Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care. Researchers and pharmaceutical companies made major strides in idiopathic pulmonary fibrosis (IPF) care this year with a host of investigational clinical trials, new…